Last updated: April 23, 2026
What are the principal supplier types for cyclopentolate hydrochloride?
Cyclopentolate hydrochloride is sourced through three main channels:
1) Generic ophthalmic API suppliers (bulk API and/or API intermediates)
2) Contract manufacturers and formulators (finished ophthalmic solutions and sterile products)
3) Chemical distributors (API and research-usage grade stock, typically via global catalog networks)
Which suppliers distribute cyclopentolate hydrochloride (API or finished ophthalmics)?
Below is a practical sourcing list by supplier archetype and product form. (Use these as starting points for RFQ and qualification because cyclopentolate hydrochloride availability can be distributor- and region-dependent.)
API and chemical distribution (catalog supply)
| Supplier |
Likely supply form(s) |
Common use case |
Sourcing notes |
| Cayman Chemical |
API / research-grade material |
Lab procurement |
Catalog-oriented ordering; request CoA/specs for QC alignment. |
| TCI Chemicals (Toronto Research Chemicals) |
API / research-grade material |
Research and method development |
Request pharmaceutical-grade documentation if intended for manufacturing. |
| Sigma-Aldrich (Merck) |
API / research-grade material |
Non-GMP usage or internal testing |
Confirm grade and documentation before GMP use. |
| Chemat / Chem-Impex / similar specialty chemical distributors |
API / intermediate supply |
Expedite sourcing |
Confirm regulatory status and batch tracing requirements. |
Ophthalmic finished dosage manufacturers (sterile product supply)
Cyclopentolate hydrochloride is primarily sold as ophthalmic solution (typically for cycloplegia and mydriasis). Finished product supply is usually through branded generic ophthalmic portfolios rather than “API-only” procurement.
| Supplier |
Likely supply form(s) |
Common use case |
Sourcing notes |
| Major ophthalmic generic brands and sterile contract manufacturers |
Finished ophthalmic solution |
Hospital and distributor channels |
Qualification hinges on sterility assurance, container closure system, and labeling compliance. |
What strengths and constraints drive supplier selection for cyclopentolate hydrochloride?
Supplier selection depends on intended use (commercial finished product vs API manufacturing vs internal analytics). Key decision drivers:
For API manufacturers
- GMP readiness: API supplied under GMP expectations for drug manufacture (documentation level and audit history matter)
- Impurity profile control: cyclopentolate hydrochloride impurity profile consistency across batches
- Salt form and assay: correct specification for hydrochloride form; consistent assay and water content if applicable
- Packaging and traceability: lot-level traceability and compliant packaging for manufacturing use
For finished ophthalmics (sterile)
- Sterility assurance: manufacturing in aseptic lines or terminal sterilization route (must match product claims)
- Dose uniformity and drop volume: critical for patient dosing consistency
- Container closure system: compatibility with cyclopentolate hydrochloride and preservatives (if any)
- Regulatory labeling: country-specific labeling and pharmacopoeial compliance
How to map cyclopentolate hydrochloride supply risk
A practical risk lens for procurement teams:
| Risk node |
What to watch |
Impact |
Typical mitigation |
| API availability |
Short runs, catalog-only suppliers, intermittent production |
Supply interruptions |
Dual-source API and lock lead times in MoQs |
| Documentation |
Research grade without GMP paperwork |
Compliance failure |
Require GMP-grade CoA/spec and audit evidence |
| Sterile supply |
Limited sterile capacity for low-volume SKUs |
Delays and shortages |
Secure backup packager or finished product source |
What product forms should be specified in RFQs?
Procurement outcomes improve when RFQs specify form and target quality documentation. RFQ language should lock:
- Cyclopentolate hydrochloride (salt form)
- Target grade: API for pharmaceutical manufacturing vs research grade
- Assay range and key impurities (request the supplier’s specification sheet)
- Package size and lead time
- GMP status and batch documentation package (CoA, impurity report, residual solvents where relevant)
Commercial sourcing playbook (actionable)
1) Source at two levels
- Level 1: API or intermediate supplier with confirmed GMP documentation
- Level 2: Finished ophthalmic supply source (if the business needs the marketed dosage form)
2) Require specification alignment before naming a supplier winner
- Ask for the supplier specification sheet and a recent CoA for cyclopentolate hydrochloride lot(s)
3) Lock audit and quality agreement early
- For API: confirm GMP certificates and whether the supplier supports DMF/ASMF pathways (where applicable in the target markets)
- For sterile product: confirm aseptic controls, sterility testing approach, and pharmacopoeial compliance
4) Use distributor networks for redundancy
- Catalog distributors can stabilize shortfalls, but they should not be the sole supplier for commercial-grade needs
Key Takeaways
- Cyclopentolate hydrochloride sourcing typically breaks into API suppliers, finished ophthalmic suppliers, and chemical distributors.
- For manufacturing-grade supply, supplier qualification must prioritize GMP documentation, impurity control, and consistent hydrochloride form specifications.
- For commercial delivery, finished ophthalmic supply depends on sterile manufacturing controls, dosing uniformity, and packaging/label compliance.
FAQs
1) Can cyclopentolate hydrochloride be sourced as research-grade material?
Yes, it is widely sold via chemical distributors, but that grade is usually unsuitable for GMP drug manufacture unless documentation and specifications are confirmed to be pharmaceutical-grade.
2) Who typically supplies cyclopentolate hydrochloride for commercial ophthalmic products?
Finished ophthalmic supply usually comes from generic ophthalmic manufacturers and sometimes sterile contract manufacturing networks, not from research chemical catalog suppliers.
3) What should procurement teams require in the first RFQ for API?
Require the latest specification sheet, a recent CoA, impurity/solvent profile information, and confirmation of GMP status.
4) What is the main supply-chain constraint for sterile ophthalmics containing cyclopentolate?
Sterile production capacity and batch release documentation are the primary constraints, especially when demand shifts to low-volume strengths or pack sizes.
5) How many suppliers are recommended for continuity?
A minimum of two qualified suppliers (API and or finished dosage, depending on the business need) reduces interruption risk when production runs tighten.
References
[1] Cayman Chemical. Cyclopentolate hydrochloride product information. https://www.caymanchem.com/
[2] TCI Chemicals. Cyclopentolate hydrochloride product information. https://www.tcichemicals.com/
[3] Merck (Sigma-Aldrich). Cyclopentolate hydrochloride product information. https://www.sigmaaldrich.com/
[4] Chem-Impex International. Cyclopentolate hydrochloride product information. https://www.chemimpex.com/
